The effects of golimumab on work productivity and quality of life among work-active axial spondyloarthritis and psoriatic arthritis patients treated in the routine care in Greece: the 'GO-UP' study.
Axial spondyloarthritis
Disease activity
Golimumab
Psoriatic arthritis
Quality of life
WPAI
Journal
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
ISSN: 1573-2649
Titre abrégé: Qual Life Res
Pays: Netherlands
ID NLM: 9210257
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
accepted:
18
11
2021
pubmed:
29
11
2021
medline:
26
4
2022
entrez:
28
11
2021
Statut:
ppublish
Résumé
To examine the impact of golimumab, on work productivity, activity limitation, and quality of life (QoL) in patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA). This real-world, multicenter, prospective study consecutively enrolled adult consented work-active patients with axSpA or PsA, newly initiated on golimumab as per the approved label. Prior receipt of > 1 prior biologic, or switching from another tumor-necrosis factor inhibitor due to primary non-response or safety reasons was not allowed. The Work Productivity and Activity Impairment-Specific Health Problem and the EuroQol 5-Dimensions (EQ-5D)-5-Level instruments were completed by the patients to assess the impact of golimumab on work productivity and activity impairment, and generic QoL, respectively. Overall, 121 eligible patients (mean age: 45.4 years; median disease duration: 11.3 months), 51 diagnosed with PsA and 70 with axSpA, were enrolled by 19 rheumatologists. Over a 11.9-month median observation period, < 1% of injections were missed (as collected by patient diaries), and the 12-month golimumab retention rate was 91.7%. At 3, 6, and 12 months post baseline, in the overall population, work productivity loss improved by a median of 31.4%, 44.2%, and 50.0%; activity impairment improved by 40.0%, 40.0%, and 50.0%; and the EQ-5D UK-weighted utility index improved by 0.24, 0.32, and 0.36 points, respectively (p < 0.001 for all). Statistically significant improvements in these measures were also noted in the PsA and axSpA subpopulations. In the routine care in Greece, golimumab displays beneficial effects on work productivity, daily activities, and QoL in work-active patients with axSpA and PsA. Trial registration number and date of registration: As per the local regulations the study has been registered at the national registry for non-interventional studies https://www.dilon.sfee.gr/studiesp_d.php?meleti_id=MK8259-6083 .
Identifiants
pubmed: 34839451
doi: 10.1007/s11136-021-03044-4
pii: 10.1007/s11136-021-03044-4
doi:
Substances chimiques
Antibodies, Monoclonal
0
golimumab
91X1KLU43E
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1385-1399Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
van der Linden, S., Valkenburg, H. A., & Cats, A. (1984). Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis and Rheumatism, 27(4), 361–368. https://doi.org/10.1002/art.1780270401
doi: 10.1002/art.1780270401
pubmed: 6231933
Rudwaleit, M., van der Heijde, D., Landewé, R., Listing, J., Akkoc, N., Brandt, J., Braun, J., Chou, C. T., Collantes-Estevez, E., Dougados, M., Huang, F., Gu, J., Khan, M. A., Kirazli, Y., Maksymowych, W. P., Mielants, H., Sørensen, I. J., Ozgocmen, S., Roussou, E., … Sieper, J. (2009). The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): Validation and final selection. Annals of the Rheumatic Diseases, 68(6), 777–783. https://doi.org/10.1136/ard.2009.108233
doi: 10.1136/ard.2009.108233
pubmed: 19297344
Braun, J. (2018). Axial spondyloarthritis including ankylosing spondylitis. Rheumatology (Oxford, England). https://doi.org/10.1093/rheumatology/key079
doi: 10.1093/rheumatology/key079
Stolwijk, C., van Onna, M., Boonen, A., & van Tubergen, A. (2016). Global prevalence of spondyloarthritis: A systematic review and meta-regression analysis. Arthritis Care & Research, 68(9), 1320–1331. https://doi.org/10.1002/acr.22831
doi: 10.1002/acr.22831
De Angelis, R., Salaffi, F., & Grassi, W. (2007). Prevalence of spondyloarthropathies in an Italian population sample: A regional community-based study. Scandinavian Journal of Rheumatology, 36(1), 14–21. https://doi.org/10.1080/03009740600904243
doi: 10.1080/03009740600904243
pubmed: 17454930
Gudu, T., & Gossec, L. (2018). Quality of life in psoriatic arthritis. Expert Review of Clinical Immunology, 14(5), 405–417. https://doi.org/10.1080/1744666X.2018.1468252
doi: 10.1080/1744666X.2018.1468252
pubmed: 29681202
Strand, V., & Singh, J. A. (2017). Patient Burden of Axial Spondyloarthritis. Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases, 23(7), 383–391. https://doi.org/10.1097/RHU.0000000000000589
doi: 10.1097/RHU.0000000000000589
Michelsen, B., Fiane, R., Diamantopoulos, A. P., Soldal, D. M., Hansen, I. J., Sokka, T., Kavanaugh, A., & Haugeberg, G. (2015). A comparison of disease burden in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. PLoS One, 10(4), e0123582. https://doi.org/10.1371/journal.pone.0123582
doi: 10.1371/journal.pone.0123582
pubmed: 25853482
pmcid: 4390320
Husted, J. A., Thavaneswaran, A., Chandran, V., Eder, L., Rosen, C. F., Cook, R. J., & Gladman, D. D. (2011). Cardiovascular and other comorbidities in patients with psoriatic arthritis: A comparison with patients with psoriasis. Arthritis Care & Research, 63(12), 1729–1735. https://doi.org/10.1002/acr.20627
doi: 10.1002/acr.20627
Khraishi, M., MacDonald, D., Rampakakis, E., Vaillancourt, J., & Sampalis, J. S. (2011). Prevalence of patient-reported comorbidities in early and established psoriatic arthritis cohorts. Clinical Rheumatology, 30(7), 877–885. https://doi.org/10.1007/s10067-011-1692-7
doi: 10.1007/s10067-011-1692-7
pubmed: 21287359
Mease, P. J., Liu, M., Rebello, S., Kang, H., Yi, E., Park, Y., & Greenberg, J. D. (2019). Comparative disease burden in patients with rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis: data from two corrona registries. Rheumatology and Therapy, 6(4), 529–542. https://doi.org/10.1007/s40744-019-00172-9
doi: 10.1007/s40744-019-00172-9
pubmed: 31529278
pmcid: 6858426
Moltó, A., & Dougados, M. (2018). Comorbidities in spondyloarthritis including psoriatic arthritis. Best practice & research. Clinical Rheumatology, 32(3), 390–400. https://doi.org/10.1016/j.berh.2018.09.002
doi: 10.1016/j.berh.2018.09.002
pubmed: 31171310
Boonen, A. (2006). A review of work-participation, cost-of-illness and cost-effectiveness studies in ankylosing spondylitis. Nature Clinical Practice. Rheumatology, 2(10), 546–553. https://doi.org/10.1038/ncprheum0297
doi: 10.1038/ncprheum0297
pubmed: 17016480
Krüger, K., Burmester, G. R., Wassenberg, S., Bohl-Bühler, M., & Thomas, M. H. (2019). Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: Non-interventional study GO-NICE in Germany. Rheumatology International, 39(1), 131–140. https://doi.org/10.1007/s00296-018-4180-4
doi: 10.1007/s00296-018-4180-4
pubmed: 30415451
Smolen, J. S., Schöls, M., Braun, J., Dougados, M., FitzGerald, O., Gladman, D. D., Kavanaugh, A., Landewé, R., Mease, P., Sieper, J., Stamm, T., Wit, M., Aletaha, D., Baraliakos, X., Betteridge, N., Bosch, F., Coates, L. C., Emery, P., Gensler, L. S., … van der Heijde, D. (2018). Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Annals of the Rheumatic Diseases, 77(1), 3–17. https://doi.org/10.1136/annrheumdis-2017-211734
doi: 10.1136/annrheumdis-2017-211734
pubmed: 28684559
Gossec, L., Smolen, J. S., Ramiro, S., de Wit, M., Cutolo, M., Dougados, M., Emery, P., Landewé, R., Oliver, S., Aletaha, D., Betteridge, N., Braun, J., Burmester, G., Cañete, J. D., Damjanov, N., FitzGerald, O., Haglund, E., Helliwell, P., Kvien, T. K., … van der Heijde, D. (2016). European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Annals of the Rheumatic Diseases, 75(3), 499–510. https://doi.org/10.1136/annrheumdis-2015-208337
doi: 10.1136/annrheumdis-2015-208337
pubmed: 26644232
Garrido-Cumbrera, M., Hillmann, O., Mahapatra, R., Trigos, D., Zajc, P., Weiss, L., Bostynets, G., Gossec, L., & Coates, L. C. (2017). Improving the Management of Psoriatic Arthritis and Axial Spondyloarthritis: Roundtable Discussions with Healthcare Professionals and Patients. Rheumatology and Therapy, 4(2), 219–231. https://doi.org/10.1007/s40744-017-0066-2
doi: 10.1007/s40744-017-0066-2
pubmed: 28600789
pmcid: 5696278
Ward, M. M., Deodhar, A., Gensler, L. S., Dubreuil, M., Yu, D., Khan, M. A., Haroon, N., Borenstein, D., Wang, R., Biehl, A., Fang, M. A., Louie, G., Majithia, V., Ng, B., Bigham, R., Pianin, M., Shah, A. A., Sullivan, N., Turgunbaev, M., … Caplan, L. (2019). 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis & Rheumatology (Hoboken, N.J.), 71(10), 1599–1613. https://doi.org/10.1002/art.41042
doi: 10.1002/art.41042
Gossec, L., Baraliakos, X., Kerschbaumer, A., de Wit, M., McInnes, I., Dougados, M., Primdahl, J., McGonagle, D. G., Aletaha, D., Balanescu, A., Balint, P. V., Bertheussen, H., Boehncke, W. H., Burmester, G. R., Canete, J. D., Damjanov, N. S., Kragstrup, T. W., Kvien, T. K., Landewé, R., … Smolen, J. S. (2020). EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Annals of the Rheumatic Diseases, 79(6), 700–712. https://doi.org/10.1136/annrheumdis-2020-217159
doi: 10.1136/annrheumdis-2020-217159
pubmed: 32434812
Simponi, Summary of Product Characteristics. Retrieved April 8, 2021, from https://www.ema.europa.eu/en/documents/product-information/simponi-epar-product-information_en.pdf
Hernandez, M. V., Sanchez-Piedra, C., Garcia-Magallon, B., Cuende, E., Manero, J., Campos-Fernandez, C., Martin-Domenech, R., Del Pino-Montes, J., Manrique, S., Castro-Villegas, M. C., Ruiz-Montesinos, D., Sanchez-Alonso, F., Diaz-Gonzalez, F., Cea-Calvo, L., Gómez-Reino, J. J., BIOBADASER Study. (2019). Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry. Rheumatology International, 39(3), 509–515. https://doi.org/10.1007/s00296-018-4177-z
doi: 10.1007/s00296-018-4177-z
pubmed: 30353269
Luttropp, K., Dozier, M., Justo, N., Cornillie, F., Kachroo, S., Govoni, M., Salomonsson, S., Black, C. M., & Khalifa, A. (2019). Real-world treatment persistence of golimumab in the management of immune-mediated rheumatic diseases in Europe: A systematic literature review. British Medical Journal Open, 9(5), e027456. https://doi.org/10.1136/bmjopen-2018-027456
doi: 10.1136/bmjopen-2018-027456
Reilly, M. C., Zbrozek, A. S., & Dukes, E. M. (1993). The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics, 4(5), 353–365. https://doi.org/10.2165/00019053-199304050-00006
doi: 10.2165/00019053-199304050-00006
pubmed: 10146874
Reilly Associates. WPAI Translation. Retrieved April 8, 2021, http://www.reillyassociates.net/WPAI_Translations.html .
EuroQol Research Foundation. EQ-5D-5L, About. Retrieved April 8, 2021, from https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/ .
Doward, L. C., Spoorenberg, A., Cook, S. A., Whalley, D., Helliwell, P. S., Kay, L. J., McKenna, S. P., Tennant, A., van der Heijde, D., & Chamberlain, M. A. (2003). Development of the ASQoL: A quality of life instrument specific to ankylosing spondylitis. Annals of the Rheumatic Diseases, 62(1), 20–26. https://doi.org/10.1136/ard.62.1.20
doi: 10.1136/ard.62.1.20
pubmed: 12480664
pmcid: 1754293
Graham, J. E., Rouse, M., Twiss, J., McKenna, S. P., & Vidalis, A. A. (2015). Greek adaptation and validation of the Ankylosing Spondylitis Quality of Life (ASQoL) measure. Hippokratia, 19(2), 119–124.
pubmed: 27418759
pmcid: 4938101
McKenna, S. P., Doward, L. C., Whalley, D., Tennant, A., Emery, P., & Veale, D. J. (2004). Development of the PsAQoL: A quality of life instrument specific to psoriatic arthritis. Annals of the Rheumatic Diseases, 63(2), 162–169. https://doi.org/10.1136/ard.2003.006296
doi: 10.1136/ard.2003.006296
pubmed: 14722205
pmcid: 1754880
Heaney, Α, Stepanous, J., McKenna, S. P., Athanassiou, P., & Vidalis, A. A. (2017). Translation and validation of the greek Psoriatic Arthritis Quality of Life Scale. Psychiatriki, 28(3), 219–225. https://doi.org/10.22365/jpsych.2017.283.219
doi: 10.22365/jpsych.2017.283.219
Garrett, S., Jenkinson, T., Kennedy, L. G., Whitelock, H., Gaisford, P., & Calin, A. (1994). A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index. The Journal of Rheumatology, 21(12), 2286–2291.
pubmed: 7699630
Yfantopoulos, J. N., & Chantzaras, A. E. (2017). Validation and comparison of the psychometric properties of the EQ-5D-3L and EQ-5D-5L instruments in Greece. The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care, 18(4), 519–531. https://doi.org/10.1007/s10198-016-0807-0
doi: 10.1007/s10198-016-0807-0
pubmed: 27262480
Salaffi, F., Ciapetti, A., Carotti, M., Gasparini, S., & Gutierrez, M. (2014). Disease activity in psoriatic arthritis: Comparison of the discriminative capacity and construct validity of six composite indices in a real world. BioMed Research International, 2014, 528105. https://doi.org/10.1155/2014/528105
doi: 10.1155/2014/528105
pubmed: 24967375
pmcid: 4055291
van Gestel, A. M., Prevoo, M. L., van’t Hof, M. A., van Rijswijk, M. H., van de Putte, L. B., & van Riel, P. L. (1996). Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis and Rheumatism, 39(1), 34–40. https://doi.org/10.1002/art.1780390105
doi: 10.1002/art.1780390105
pubmed: 8546736
Fleischmann, R. M., van der Heijde, D., Gardiner, P. V., Szumski, A., Marshall, L., & Bananis, E. (2017). DAS28-CRP and DAS28-ESR cut-offs for high disease activity in rheumatoid arthritis are not interchangeable. RMD Open, 3(1), e000382. https://doi.org/10.1136/rmdopen-2016-000382
doi: 10.1136/rmdopen-2016-000382
pubmed: 28255449
pmcid: 5294021
Krüger, K., Remstedt, S., Thiele, A., & Klaudius, I. (2017). Golimumab Improves Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA): Interim Results from a Non-Interventional Trial in Germany [abstract]. Arthritis Rheumatol 69 (suppl 10). Retrieved March 4, 2018, from http://acrabstracts.org/abstract/golimumab-improves-work-productivity-and-activity-impairment-in-patients-with-rheumatoid-arthritis-ra-ankylosing-spondylitis-as-and-psoriatic-arthritis-psa-interim-results-from-a-non-intervent/ .
Xu, H., & Yin, J. (2019). HLA risk alleles and gut microbiome in ankylosing spondylitis and rheumatoid arthritis Best practice & research. Clinical Rheumatology, 33(6), 101499. https://doi.org/10.1016/j.berh.2020.101499
doi: 10.1016/j.berh.2020.101499
pubmed: 32279929
Colmegna, I., Cuchacovich, R., & Espinoza, L. R. (2004). HLA-B27-associated reactive arthritis: Pathogenetic and clinical considerations. Clinical Microbiology Reviews, 17(2), 348–369. https://doi.org/10.1128/CMR.17.2.348-369.2004
doi: 10.1128/CMR.17.2.348-369.2004
pubmed: 15084505
pmcid: 387405
Wakefield, D., Clarke, D., & McCluskey, P. (2021). Recent Developments in HLA B27 Anterior Uveitis. Frontiers in Immunology, 11, 608134. https://doi.org/10.3389/fimmu.2020.608134
doi: 10.3389/fimmu.2020.608134
pubmed: 33469457
pmcid: 7813675
Krueger, K., Remstedt, S., Thiele, A., & Hohenberger, S. (2020). Golimumab improves patient-reported outcomes in daily practice of inflammatory rheumatic diseases in Germany. Journal of Comparative Effectiveness Research, 9(12), 891–902. https://doi.org/10.2217/cer-2020-0092
doi: 10.2217/cer-2020-0092
pubmed: 32722921
Claudepierre, P., Van den Bosch, F., Sarzi-Puttini, P., Vastesaeger, N., Govoni, M., & Kachroo, S. (2019). Treatment with golimumab or infliximab reduces health resource utilization and increases work productivity in patients with ankylosing spondylitis in the QUO-VADIS study, a large, prospective real-life cohort. International Journal of Rheumatic Diseases, 22(6), 995–1001. https://doi.org/10.1111/1756-185X.13526
doi: 10.1111/1756-185X.13526
pubmed: 30989813
Dejaco, C., Mueller, T., Zamani, O., Kurtz, U., Egger, S., Resch-Passini, J., Totzauer, A., Eisterer, W., Yazdani-Biuki, B., Schwingenschloegl, T., Peichl, P., Kraus, A., Naerr, G. W., & Rickert, V. (2018). FRI0108 Golimumab improves work productivity and activity and quality of life in patients with rheumatoid arthritis (RA), psoriasis arthritis (PSA) and axial spondyloarthritis (AxSPA): interim results from a non-interventional study in Austria (Go Active). Annals of Rheumatic Diseases, 77(598), 2–599. https://doi.org/10.1136/annrheumdis-2018-eular.2411
doi: 10.1136/annrheumdis-2018-eular.2411
Szende, A., Janssen, B., & Cabasés, J. (2014). Self-Reported Population Health: An International Perspective Based on EQ-5D. Springer Dordrecht Heidelberg New York, London. 2014. Springer Open. Retrieved September 17, 2020 from https://eq-5dpublications.euroqol.org/download?id=0_54006&fileId=54415 .
Kontodimopoulos, N., Pappa, E., Niakas, D., Yfantopoulos, J., Dimitrakaki, C., & Tountas, Y. (2008). Validity of the EuroQoL (EQ-5D) instrument in a Greek general population. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 11(7), 1162–1169. https://doi.org/10.1111/j.1524-4733.2008.00356.x
doi: 10.1111/j.1524-4733.2008.00356.x
Sidiropoulos, P., Bounas, A., Athanassiou, P., Koutsianas, C., Petrikkou, E., Kaltsonoudis, E., Drosos, A., & Vassilopoulos, D. (2020). Correlation of patient preferences to treatment outcomes in patients with rheumatoid arthritis treated with tumour necrosis factor inhibitors in Greece. Clinical Rheumatology, 39(12), 3643–3652. https://doi.org/10.1007/s10067-020-05171-8
doi: 10.1007/s10067-020-05171-8
pubmed: 32458235
Iannone, F., Santo, L., Anelli, M. G., Bucci, R., Semeraro, A., Quarta, L., D’Onofrio, F., Marsico, A., Carlino, G., Casilli, O., Cacciapaglia, F., Zuccaro, C., Falappone, P. C., Cantatore, F. P., Muratore, M., & Lapadula, G. (2017). Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Seminars in Arthritis and Rheumatism, 47(1), 108–114. https://doi.org/10.1016/j.semarthrit.2017.01.008
doi: 10.1016/j.semarthrit.2017.01.008
pubmed: 28216195
Manara, M., Caporali, R., Favalli, E. G., Grosso, V., Atzeni, F., Sarzi Puttini, P., Gorla, R., Bazzani, C., Fusaro, E., Pellerito, R., Rocchetta, P. A., & Sinigaglia, L. (2017). Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: Data from the LORHEN registry. Clinical and Experimental Rheumatology, 35(5), 804–809.
pubmed: 28770712
Thomas, K., Flouri, I., Repa, A., Fragiadaki, K., Sfikakis, P. P., Koutsianas, C., Kaltsonoudis, E., Voulgari, P. V., Drosos, A. A., Petrikkou, E., Sidiropoulos, P., & Vassilopoulos, D. (2018). High 3-year golimumab survival in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: Real world data from 328 patients. Clinical and Experimental Rheumatology, 36(2), 254–262.
pubmed: 29148406
Sieper, J., van der Heijde, D., Dougados, M., Maksymowych, W. P., Scott, B. B., Boice, J. A., Berd, Y., Bergman, G., Curtis, S., Tzontcheva, A., Huyck, S., & Weng, H. H. (2015). A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Arthritis & Rheumatology (Hoboken, N.J.), 67(10), 2702–2712. https://doi.org/10.1002/art.39257
doi: 10.1002/art.39257
Van den Bosch, F., Flipo, R. M., Braun, J., Vastesaeger, N., Kachroo, S., & Govoni, M. (2019). Clinical and quality of life improvements with golimumab or infliximab in a real-life ankylosing spondylitis population: The QUO-VADIS study. Clinical and Experimental Rheumatology, 37(2), 199–207.
pubmed: 30148434
Reveille, J. D., Deodhar, A., Caldron, P. H., Dudek, A., Harrison, D. D., Kim, L., Lo, K. H., Leu, J. H., & Hsia, E. C. (2019). Safety and efficacy of intravenous golimumab in adults with ankylosing spondylitis: Results through 1 year of the GO-ALIVE study. The Journal of Rheumatology, 46(10), 1277–1283. https://doi.org/10.3899/jrheum.180718
doi: 10.3899/jrheum.180718
pubmed: 30824635
Kavanaugh, A., McInnes, I. B., Krueger, G. G., Gladman, D., Beutler, A., Gathany, T., Mack, M., Tandon, N., Han, C., & Mease, P. (2013). Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: Findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Care & Research, 65(10), 1666–1673. https://doi.org/10.1002/acr.22044
doi: 10.1002/acr.22044
van der Heijde, D., Deodhar, A., Braun, J., Mack, M., Hsu, B., Gathany, T. A., Inman, R. D., Han, C., & GO-RAISE investigators,. (2014). The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial. The Journal of Rheumatology, 41(6), 1095–1103. https://doi.org/10.3899/jrheum.131003
doi: 10.3899/jrheum.131003
pubmed: 24737912
Huang, J. C., Qian, B. P., Qiu, Y., Wang, B., Yu, Y., Zhu, Z. Z., Hu, J., & Qu, Z. (2017). Quality of life and correlation with clinical and radiographic variables in patients with ankylosing spondylitis: A retrospective case series study. BMC Musculoskeletal Disorders, 18(1), 352. https://doi.org/10.1186/s12891-017-1711-1
doi: 10.1186/s12891-017-1711-1
pubmed: 28810915
pmcid: 5558739
Bodur, H., Ataman, S., Rezvani, A., Buğdaycı, D. S., Cevik, R., Birtane, M., Akıncı, A., Altay, Z., Günaydın, R., Yener, M., Koçyiğit, H., Duruöz, T., Yazgan, P., Cakar, E., Aydın, G., Hepgüler, S., Altan, L., Kırnap, M., Olmez, N., … Günendi, Z. (2011). Quality of life and related variables in patients with ankylosing spondylitis. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation, 20(4), 543–549. https://doi.org/10.1007/s11136-010-9771-9
doi: 10.1007/s11136-010-9771-9
Dean, L. E., Macfarlane, G. J., & Jones, G. T. (2018). Five potentially modifiable factors predict poor quality of life in ankylosing spondylitis: results from the scotland registry for ankylosing spondylitis. The Journal of Rheumatology, 45(1), 62–69. https://doi.org/10.3899/jrheum.160411
doi: 10.3899/jrheum.160411
pubmed: 28765244
Machado, P., & van der Heijde, D. (2011). How to measure disease activity in axial spondyloarthritis? Current Opinion in Rheumatology, 23(4), 339–345. https://doi.org/10.1097/BOR.0b013e3283470f23
doi: 10.1097/BOR.0b013e3283470f23
pubmed: 21519269
Nell-Duxneuner, V. P., Stamm, T. A., Machold, K. P., Pflugbeil, S., Aletaha, D., & Smolen, J. S. (2010). Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis. Annals of the Rheumatic Diseases, 69(3), 546–549. https://doi.org/10.1136/ard.2009.117945
doi: 10.1136/ard.2009.117945
pubmed: 19762363
Schoels, M. M., Aletaha, D., Alasti, F., & Smolen, J. S. (2016). Disease activity in psoriatic arthritis (PsA): Defining remission and treatment success using the DAPSA score. Annals of the Rheumatic Diseases, 75(5), 811–818. https://doi.org/10.1136/annrheumdis-2015-207507
doi: 10.1136/annrheumdis-2015-207507
pubmed: 26269398
Tucker, L. J., Coates, L. C., & Helliwell, P. S. (2019). Assessing disease activity in psoriatic arthritis: A literature review. Rheumatology and Therapy, 6(1), 23–32. https://doi.org/10.1007/s40744-018-0132-4
doi: 10.1007/s40744-018-0132-4
pubmed: 30471015